BioView and Transgenomic Enter into Distribution Agreement
News Nov 07, 2007
BioView Ltd. of Israel and Transgenomic, Inc. of Nebraska announced that they have entered into an agreement allowing Transgenomic to distribute BioView's family of Scanning and Analysis Workstations in selected Western European countries and Scandinavia.
Transgenomic's European sales and support organization will market, sell and service the instruments. BioView's products include the Duet, Allegro and Accord automated workstations for the scanning and classification of cells via fluorescence in-situ hybridization (FISH) and brightlight microscopy. The results of the scan are reviewed on the BioView Solo offline workstation for the final report.
The BioView products are intended for in-vitro diagnostic use as an aiding tool to the pathologist in the detection, classification and counting of cells of interest based on color, intensity, size, pattern, and shape.
The BioView products have applications for testing in hematological disorders, breast cancer studies for Her-2 neu gene amplification, bladder cancer screening and follow up using Vysis UroVysion™ Bladder Cancer Recurrence Kit and prenatal and postnatal genetic testing.
Dr. Opher Shapira, President and CEO of BioView Ltd., views this agreement as an opportunity for BioView to expand its market penetration in Europe in an efficient manner.
According to Shapira, "Transgenomic has a reputation amongst its European customer base for providing superior service and support. Following our success in the U.S. market, we believe that this agreement with Transgenomic will help establish us in a similar manner in the Western European and Scandinavian countries covered by this agreement."
Craig Tuttle, President and CEO of Transgenomic added, "We are very excited to add BioView's world-leading imaging platforms to our cytogenetics portfolio of products. These sophisticated imaging systems will complement our HANABI Metaphase Chromosome Harvester and spreader products and further expand our sales and service reach into cytogenetics and pathology laboratories across Europe."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.